Ionis Pharmaceuticals, Inc.
IONS
Rankning i aktier
#2564
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Aktiekurs
$44.92
Marknadsvärde
$7.46B
Förändring (1 dag)
-1.07%
Förändring (1 år)
-37.30%
Land
US
Handel Ionis Pharmaceuticals, Inc. (IONS)
Kategori
Healthcare
Intäkter för Ionis Pharmaceuticals, Inc. (IONS)
Intäkter i Jun 2026 TTM: $873.76M
Enligt Ionis Pharmaceuticals, Inc. senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $873.76M. År 2023 hade företaget intäkter på $787.65M en ökning jämfört med intäkterna år 2022, som var $587.37M. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäktshistorik för Ionis Pharmaceuticals, Inc. från 2000 till 2026
Intäkter vid slutet av varje år
| År | Intäkter | Ändra |
|---|---|---|
| 2026 (TTM) | $873.76M | 23.91% |
| 2024 | $705.14M | -10.48% |
| 2023 | $787.65M | 34.10% |
| 2022 | $587.37M | -27.53% |
| 2021 | $810.46M | 11.13% |
| 2020 | $729.26M | -35.04% |
| 2019 | $1.12B | 87.20% |
| 2018 | $599.67M | 16.63% |
| 2017 | $514.18M | 37.93% |
| 2016 | $372.78M | 31.40% |
| 2015 | $283.70M | 32.47% |
| 2014 | $214.16M | 45.41% |
| 2013 | $147.29M | 44.33% |
| 2012 | $102.05M | 2.99% |
| 2011 | $99.09M | -8.65% |
| 2010 | $108.47M | -10.80% |
| 2009 | $121.60M | 13.44% |
| 2008 | $107.19M | 83.72% |
| 2007 | $58.34M | 292.65% |
| 2006 | $14.86M | -62.98% |
| 2005 | $40.13M | -5.84% |
| 2004 | $42.62M | -14.73% |
| 2003 | $49.99M | -37.65% |
| 2002 | $80.18M | 50.51% |
| 2001 | $53.27M | 43.00% |
| 2000 | $37.26M | 0.00% |
Intäkter för liknande företag eller konkurrenter
| Företag | Intäkter | Intäktsdifferens | Land |
|---|---|---|---|
| $12.62B | 1,344.83% |
US
|
|
| $2.23B | 154.99% |
US
|
|
| $15.74B | 1,701.91% |
AU
|
|
| $6.02B | 589.12% |
NL
|
|
| - | - |
CH
|
